BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection

ABSTRACT: Background: To explore Bacillus Calmette-Guérin vaccine (BCG) as a protective factor against tuberculosis (TB) and how human immunodeficiency virus (HIV) infection modifies the effect of BCG on TB. Methods: Two matched case-control studies were conducted. One study compared TB cases and co...

Full description

Autores:
Arbeláez Montoya, María Patricia
Nelson, Kenrad E.
Muñoz, Álvaro
Tipo de recurso:
Article of investigation
Fecha de publicación:
2000
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/33975
Acceso en línea:
https://hdl.handle.net/10495/33975
Palabra clave:
Tuberculosis
Vacuna BCG
BCG Vaccine
Infecciones por VIH
HIV Infections
Estudios de Casos y Controles
Case-Control Studies
Colombia - epidemiología
Colombia - epidemiology
Ensayo de Inmunoadsorción Enzimática
Enzyme-Linked Immunosorbent Assay
Comorbilidad
Comorbidity
Resultado del Tratamiento
Treatment Outcome
Rights
openAccess
License
http://creativecommons.org/licenses/by-sa/2.5/co/
id UDEA2_7ff7cf4549d877e17593439f3700ea4e
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/33975
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
title BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
spellingShingle BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
Tuberculosis
Vacuna BCG
BCG Vaccine
Infecciones por VIH
HIV Infections
Estudios de Casos y Controles
Case-Control Studies
Colombia - epidemiología
Colombia - epidemiology
Ensayo de Inmunoadsorción Enzimática
Enzyme-Linked Immunosorbent Assay
Comorbilidad
Comorbidity
Resultado del Tratamiento
Treatment Outcome
title_short BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
title_full BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
title_fullStr BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
title_full_unstemmed BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
title_sort BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
dc.creator.fl_str_mv Arbeláez Montoya, María Patricia
Nelson, Kenrad E.
Muñoz, Álvaro
dc.contributor.author.none.fl_str_mv Arbeláez Montoya, María Patricia
Nelson, Kenrad E.
Muñoz, Álvaro
dc.contributor.researchgroup.spa.fl_str_mv Políticas Sociales y Servicios de Salud
Epidemiología
dc.subject.decs.none.fl_str_mv Tuberculosis
Vacuna BCG
BCG Vaccine
Infecciones por VIH
HIV Infections
Estudios de Casos y Controles
Case-Control Studies
Colombia - epidemiología
Colombia - epidemiology
Ensayo de Inmunoadsorción Enzimática
Enzyme-Linked Immunosorbent Assay
Comorbilidad
Comorbidity
Resultado del Tratamiento
Treatment Outcome
topic Tuberculosis
Vacuna BCG
BCG Vaccine
Infecciones por VIH
HIV Infections
Estudios de Casos y Controles
Case-Control Studies
Colombia - epidemiología
Colombia - epidemiology
Ensayo de Inmunoadsorción Enzimática
Enzyme-Linked Immunosorbent Assay
Comorbilidad
Comorbidity
Resultado del Tratamiento
Treatment Outcome
description ABSTRACT: Background: To explore Bacillus Calmette-Guérin vaccine (BCG) as a protective factor against tuberculosis (TB) and how human immunodeficiency virus (HIV) infection modifies the effect of BCG on TB. Methods: Two matched case-control studies were conducted. One study compared TB cases and controls who were HIV positive. The second compared TB cases and controls who were HIV negative. The study population consisted of 88 TB cases and 88 controls among HIV-positive individuals and 314 TB cases and 310 controls among HIV-negative individuals. Cases were new TB diagnoses, confirmed by either bacteriology, pathology, radiology or clinical response to treatment; controls were selected from people without TB symptoms and who sought medical attention in the same institution where a case was enrolled. BCG was assessed by the presence of a typical scar. Results: The level of protection against all clinical forms of TB was 22% among HIV positive individuals (odds ratio [OR] = 0.78, 95% CI : 0.48-1.26) and 26% among HIV negatives (OR = 0.74, 95% CI : 0.52-1.05). There was a significant difference (P = 0.002) in the level of protection against extrapulmonary TB (ETB) between HIV-negative (OR = 0.54, 95% CI : 0.32-0.93) and HIV-positive individuals (OR = 1.36, 95% CI : 0.72-2.57). Conclusion: BCG has a modest protective effect against all forms of TB independent of HIV status, and BCG confers protection against extrapulmonary TB among HIV-negative individuals. However, HIV infection seems to abrogate the protective effect of BCG against extrapulmonary TB. Our data support the public health importance of BCG vaccine in the prevention of extrapulmonary TB among immunocompetent individuals.
publishDate 2000
dc.date.issued.none.fl_str_mv 2000
dc.date.accessioned.none.fl_str_mv 2023-03-14T01:00:04Z
dc.date.available.none.fl_str_mv 2023-03-14T01:00:04Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Arbeláez MP, Nelson KE, Muñoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol. 2000 Dec;29(6):1085-91. doi: 10.1093/ije/29.6.1085.
dc.identifier.issn.none.fl_str_mv 0300-5771
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/33975
dc.identifier.doi.none.fl_str_mv 10.1093/ije/29.6.1085
dc.identifier.eissn.none.fl_str_mv 1464-3685
identifier_str_mv Arbeláez MP, Nelson KE, Muñoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol. 2000 Dec;29(6):1085-91. doi: 10.1093/ije/29.6.1085.
0300-5771
10.1093/ije/29.6.1085
1464-3685
url https://hdl.handle.net/10495/33975
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Int. J. Epidemiol.
dc.relation.citationendpage.spa.fl_str_mv 1091
dc.relation.citationissue.spa.fl_str_mv 6
dc.relation.citationstartpage.spa.fl_str_mv 1085
dc.relation.citationvolume.spa.fl_str_mv 29
dc.relation.ispartofjournal.spa.fl_str_mv International Journal of Epidemiology
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-sa/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-sa/2.5/co/
https://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 7
dc.format.mimetype.spa.fl_str_mv aplicatión/pdf
dc.publisher.spa.fl_str_mv International Epidemiological Association
dc.publisher.place.spa.fl_str_mv Londres, Inglaterra
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/79043a23-ec17-455b-bbee-a177d85a618e/download
https://bibliotecadigital.udea.edu.co/bitstreams/bce15106-b569-47a0-989a-901bab2e11c6/download
https://bibliotecadigital.udea.edu.co/bitstreams/2a84e422-144c-416f-9d63-7c50296b44e8/download
https://bibliotecadigital.udea.edu.co/bitstreams/c97a86a7-2f25-422f-8cc5-ceb3c0258489/download
https://bibliotecadigital.udea.edu.co/bitstreams/828da63c-5395-46c5-8496-b1fc92f1ac45/download
bitstream.checksum.fl_str_mv 55f1739726ebfd1055222e9c1bfb54a9
21f304c81bfa79d3db42c7e2740dd6fe
8a4605be74aa9ea9d79846c1fba20a33
8acf59c202e23b0d9f0fac45d02b6ef0
1b5b96575b51af7b04dab54612222b5b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052226338881536
spelling Arbeláez Montoya, María PatriciaNelson, Kenrad E.Muñoz, ÁlvaroPolíticas Sociales y Servicios de SaludEpidemiología2023-03-14T01:00:04Z2023-03-14T01:00:04Z2000Arbeláez MP, Nelson KE, Muñoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol. 2000 Dec;29(6):1085-91. doi: 10.1093/ije/29.6.1085.0300-5771https://hdl.handle.net/10495/3397510.1093/ije/29.6.10851464-3685ABSTRACT: Background: To explore Bacillus Calmette-Guérin vaccine (BCG) as a protective factor against tuberculosis (TB) and how human immunodeficiency virus (HIV) infection modifies the effect of BCG on TB. Methods: Two matched case-control studies were conducted. One study compared TB cases and controls who were HIV positive. The second compared TB cases and controls who were HIV negative. The study population consisted of 88 TB cases and 88 controls among HIV-positive individuals and 314 TB cases and 310 controls among HIV-negative individuals. Cases were new TB diagnoses, confirmed by either bacteriology, pathology, radiology or clinical response to treatment; controls were selected from people without TB symptoms and who sought medical attention in the same institution where a case was enrolled. BCG was assessed by the presence of a typical scar. Results: The level of protection against all clinical forms of TB was 22% among HIV positive individuals (odds ratio [OR] = 0.78, 95% CI : 0.48-1.26) and 26% among HIV negatives (OR = 0.74, 95% CI : 0.52-1.05). There was a significant difference (P = 0.002) in the level of protection against extrapulmonary TB (ETB) between HIV-negative (OR = 0.54, 95% CI : 0.32-0.93) and HIV-positive individuals (OR = 1.36, 95% CI : 0.72-2.57). Conclusion: BCG has a modest protective effect against all forms of TB independent of HIV status, and BCG confers protection against extrapulmonary TB among HIV-negative individuals. However, HIV infection seems to abrogate the protective effect of BCG against extrapulmonary TB. Our data support the public health importance of BCG vaccine in the prevention of extrapulmonary TB among immunocompetent individuals.COL0014789COL00043627aplicatión/pdfengInternational Epidemiological AssociationLondres, Inglaterrahttp://creativecommons.org/licenses/by-sa/2.5/co/https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infectionArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTuberculosisVacuna BCGBCG VaccineInfecciones por VIHHIV InfectionsEstudios de Casos y ControlesCase-Control StudiesColombia - epidemiologíaColombia - epidemiologyEnsayo de Inmunoadsorción EnzimáticaEnzyme-Linked Immunosorbent AssayComorbilidadComorbidityResultado del TratamientoTreatment OutcomeInt. J. Epidemiol.10916108529International Journal of EpidemiologyPublicationORIGINALArbalaezMaria_2000_BCGVaccineEffectiveness.pdfArbalaezMaria_2000_BCGVaccineEffectiveness.pdfArtículo de investigaciónapplication/pdf192029https://bibliotecadigital.udea.edu.co/bitstreams/79043a23-ec17-455b-bbee-a177d85a618e/download55f1739726ebfd1055222e9c1bfb54a9MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81045https://bibliotecadigital.udea.edu.co/bitstreams/bce15106-b569-47a0-989a-901bab2e11c6/download21f304c81bfa79d3db42c7e2740dd6feMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/2a84e422-144c-416f-9d63-7c50296b44e8/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTArbalaezMaria_2000_BCGVaccineEffectiveness.pdf.txtArbalaezMaria_2000_BCGVaccineEffectiveness.pdf.txtExtracted texttext/plain33619https://bibliotecadigital.udea.edu.co/bitstreams/c97a86a7-2f25-422f-8cc5-ceb3c0258489/download8acf59c202e23b0d9f0fac45d02b6ef0MD54falseAnonymousREADTHUMBNAILArbalaezMaria_2000_BCGVaccineEffectiveness.pdf.jpgArbalaezMaria_2000_BCGVaccineEffectiveness.pdf.jpgGenerated Thumbnailimage/jpeg13660https://bibliotecadigital.udea.edu.co/bitstreams/828da63c-5395-46c5-8496-b1fc92f1ac45/download1b5b96575b51af7b04dab54612222b5bMD55falseAnonymousREAD10495/33975oai:bibliotecadigital.udea.edu.co:10495/339752025-03-26 18:56:19.392http://creativecommons.org/licenses/by-sa/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=